NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study
1 other identifier
interventional
49
1 country
1
Brief Summary
This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 30, 2022
CompletedFirst Posted
Study publicly available on registry
January 11, 2023
CompletedStudy Start
First participant enrolled
August 29, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
ExpectedMay 16, 2025
March 1, 2025
1.9 years
October 30, 2022
May 13, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Mean change in neuron-specific enolase (NSE)
The mean change in concentration of NSE from baseline levels to 72 hours post-ROSC.
72 hours post ROSC
Secondary Outcomes (13)
Peak concentration of myocardial injury biomarker - High-sensitive troponin (hsTNT)
Within 72hours of ROSC
Peak concentration of myocardial injury biomarker - N-terminal pro b-type natriuretic peptide (NT-proBNP)
Within 72hours of ROSC
Peak concentration of renal function - Creatinine
Within 72hours of ROSC
Peak concentration of renal injury biomarker - Proenkephalin A 119-159 (penKID)
Within 72hours of ROSC
Peak concentration of renal injury biomarker - Biologically active adrenomedullin (bio-ADM)
Within 72hours of ROSC
- +8 more secondary outcomes
Other Outcomes (1)
Exploratory outcome - Digital neurocognitive assessment
Through study completion, average of 12 months post OHCA
Study Arms (1)
Individualized blood pressure strategy
EXPERIMENTALHemodynamic optimization performed to an individualized target mean arterial pressure in the first 72 hours post ROSC based on cerebral perfusion assessed serially.
Interventions
An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
Eligibility Criteria
You may qualify if:
- At least 21 years of age
- Comatose defined as not being able to obey verbal commands and no verbal response to pain after sustained ROSC.
You may not qualify if:
- ≥ 80 years old at time of enrolment
- Pregnant patients
- Limitations of care or life support therapy withdrawn within 24 hours of admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National University Heart Centre, Singapore
Singapore, Singapore
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shir Lynn Lim
National University Hospital, Singapore
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 30, 2022
First Posted
January 11, 2023
Study Start
August 29, 2023
Primary Completion
August 1, 2025
Study Completion (Estimated)
August 1, 2026
Last Updated
May 16, 2025
Record last verified: 2025-03